Cited by 42Liver Disease and TransplantationGastrointestinal motility and disordersGut microbiota and health

Effect of cisapride on intestinal bacterial and endotoxin translocation in cirrhosis

Open access
Zhang, Shun-Cai·2003·World Journal of Gastroenterology

Abstract

AIM: To investigate the effects of cisapride on intestinal bacterial overgrowth (IBO), bacterial and endotoxin translocation, intestinal transit and permeability in cirrhotic rats. METHODS: All animals were assessed with variables including bacterial and endotoxin translocation, intestinal bacterial overgrowth, intestinal transit and permeability. Bacterial translocation (BT) was assessed by bacterial culture of MLN, liver and spleen, IBO by a jejunal bacterial count of the specific organism, intestinal permeability by determination of the 24-hour urinary (99m)Tc-DTPA excretion and intestinal transit by measurement of the distribution of (51)Cr in the intestine. RESULTS: Bacterial translocation (BT) and IBO was found in 48 % and 80 % cirrhotic rats respectively and none in control rats. Urinary excretion of (99m)Tc-DTPA in cirrhotic rats with BT (22.2+/-7.8) was greater than these without BT (10.5+/-2.9). Intestinal transit (geometric center ratio) was significantly delayed in cirrhotic rats (0.31+/-0.06) and further more delayed in cirrhotic rats with BT (0.24+/-0.06) than these without BT (0.38+/-0.11). Cirrhotic rats with IBO had significantly higher rates of intestinal bacterial and endotoxin translocation, slower intestinal transit time and higher intestinal permeability than those without IBO. It was also found that BT was closely associated with IBO and the injury of intestinal barrier. Compared with the placebo group, cisapride-treated rats had lower rates of bacterial/endotoxin translocation and IBO, which was closely associated with increased intestinal transit and improved intestinal permeability by cisapride. CONCLUSION: These results indicate that endotoxin and bacterial translocation in cirrhotic rats may be attributed to IBO and increased intestinal permeability. Cisapride that accelerates intestinal transit and improve intestinal permeability might be helpful in preventing intestinal bacterial and endotoxin translocation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3748/wjg.v9.i3.534

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cisapride decreases intestinal transit time and inhibits intestinal bacterial overgrowth and bacterial translocation in animal models and cirrhosis patients.

    “The prokinetic drug cisapride not only decreases intestinal transit time but also inhibits intestinal bacterial overgrowth and bacterial translocation, both in animal models150,151 and in patients with cirrhosis150,152.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Plummer JL, Ossowicz CJ, Whibley C, Ilsley AH, Hall PD. Influ- ence of intestinal flora on the development of fibrosis and cir- rhosis in rat model. J Gastroenterol Hepatol 2000; 15: 1307-1311

Cited by

Sorted by citations

Authors
Zhang, S.-C.
Venue
World Journal of Gastroenterology
Published
2003
Volume
9
Issue
3
Pages
534
ISSN
1007-9327 (ISSN-L)
OpenAlex
W1543160998
Cited by
42
References
34
Citations by year
2022: 1 · 2021: 1 · 2020: 1 · 2019: 1 · 2018: 2 · 2017: 5 · 2016: 2 · 2015: 1 · 2014: 2 · 2013: 2 · 2012: 3
FWCI
2.40
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • World Journal of Gastroenterology (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
cisapride, intestinal bacterial overgrowth, bacterial translocation, endotoxin translocation, liver cirrhosis, intestinal transit, intestinal permeability, intestinal barrier injury
MeSH terms
Animals, Bacteria, Biological Transport, Endotoxins, Gastrointestinal Agents, Gastrointestinal Transit, Intestinal Mucosa, Intestines, Liver Cirrhosis, Experimental, Male, Rats, Sprague-Dawley, Bacterial Physiological Phenomena, Bacterial Translocation, Cisapride, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review